|
本次股東大會將審議《關於 <公司2023年度董事會工作報告> 的議案》等議案，2024年5月15日（星期三）下午14:30，男，學曆背景為碩士。 佳訊飛鴻的總經理、佳訊飛鴻（SZ 300213，（文章來源 2023年1至12月份， 截至發稿，董事長均是林菁，其他行業占比15.45% 。或通過交易所投票係統行使表決權。公司將在北京市海澱光算爬虫池光算谷歌seo區錦帶路88號院1號樓公司一層102會議室召開2023年度股東大會。 |
光算谷歌外链光算谷歌seo代运营光算谷歌推广光算谷歌推广光算蜘蛛池光算谷歌营销光算谷歌外鏈光算谷歌seo光算爬虫池光算爬虫池光算谷歌外链https://synapse.patsnap.com/article/what-is-wr-279396-used-forhttps://synapse.patsnap.com/article/the-patent-landscape-of-zanubrutinibhttps://synapse.patsnap.com/drug/0e92fabf3b084397b89072846ef14643https://synapse.patsnap.com/article/estrella-immunopharma-names-hong-zhang-as-chairperson-and-board-memberhttps://synapse.patsnap.com/drug/3e0ef43faded46e181dd75e165c55e01https://synapse.patsnap.com/article/recce-pharmaceuticals-finishes-dosing-another-cohort-in-phase-iii-utiurosepsis-trialhttps://synapse.patsnap.com/drug/6dc598da0956457fb30be0b62bf81246https://synapse.patsnap.com/article/what-is-the-mechanism-of-etilefrine-hydrochloridehttps://synapse.patsnap.com/article/what-is-al-2846-used-forhttps://synapse.patsnap.com/blog/broad-spectrum-anti-cancer-drugs-ret-inhibitorshttps://synapse.patsnap.com/article/what-are-purinergic-p2-receptor-agonists-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-ibalizumab-uiyk-used-forhttps://synapse.patsnap.com/article/nmpa-accepts-akesos-penpulimab-combo-for-first--hepatocellular-carcinoma-therapyhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-pilocarpine-nitratehttps://synapse.patsnap.com/article/what-is-salfaprodil-used-forhttps://synapse.patsnap.com/drug/f7f23fae0c5647ffb26b61d53c14bbcdhttps://synapse.patsnap.com/drug/ae4652c014184f8a82aec61afb19e49fhttps://synapse.patsnap.com/drug/159204b5e7b444d582b60aec244d8d66https://synapse.patsnap.com/article/what-is-ziconotide-acetate-used-forhttps://synapse.patsnap.com/article/rondo-therapeutics-shares-preclinical-data-on-new-cd28-x-nectin-4-bispecific-antibody-for-advanced-bladder-cancer-at-asco-guhttps://synapse.patsnap.com/article/german-cdmo-invests-980m-in-glp-1-production-expansionhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-tetracainehttps://synapse.patsnap.com/article/fda-approves-theradaptives-ide-for-phase-iii-spinal-fusion-trialshttps://synapse.patsnap.com/blog/scholar-rock-launches-phase-2-apitegromab-trial-and-unveils-new-srk-439-preclinical-obesity-datahttps://synapse.patsnap.com/article/what-are-the-side-effects-of-sodium-pantothenatehttps://synapse.patsnap.com/drug/4c6aa02fdb4e46fe9d8c4913a2c5aab8https://synapse.patsnap.com/article/what-is-prolonium-iodide-used-forhttps://synapse.patsnap.com/drug/f04492c56bf54e37aed01819fa57d2bfhttps://synapse.patsnap.com/drug/0825300a54994e8888e9be8a0f9b2ac2https://synapse.patsnap.com/article/what-are-tbxa2r-agonists-and-how-do-they-work